Alder BioPharmaceuticals, Inc.(NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, announced today new six-month data from its PROMISE 2 Phase 3 clinical trial in patients with chronic migraine following a second quarterly infusion of eptinezumab.
The data show that patients experienced a reduction of 8.8 monthly migraine days (MMDs) from baseline following the second quarterly infusion of 300 mg of eptinezumab. These results demonstrate a further numerical improvement in efficacy over the first infusion which resulted in a reduction from baseline of 8.2 MMDs in this trial. Eptinezumab is Alder’s lead investigational product candidate for migraine prevention targeting calcitonin gene-related peptide (CGRP). Detailed results will be presented today at the 60th AHS Annual Scientific Meeting in San Francisco, CA.
‘These data further add to the significant body of clinical evidence supporting eptinezumab’s encouraging clinical profile and reinforce our belief in the value it may provide to patients, if approved’ said Robert Azelby, chief executive officer of Alder. ‘The robust efficacy shown over the two quarterly infusions of eptinezumab in chronic migraine patients continues to support eptinezumab’s potential as an important treatment option for patients living with this debilitating condition.’
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.